Loading...
XKRX
069620
Market cap1.01bUSD
Jul 10, Last price  
131,900.00KRW
1D
0.23%
1Q
-12.30%
Jan 2017
91.99%
IPO
283.90%
Name

Daewoong Pharma

Chart & Performance

D1W1MN
XKRX:069620 chart
P/E
7.75
P/S
0.97
EPS
17,021.64
Div Yield, %
0.46%
Shrs. gr., 5y
1.68%
Rev. gr., 5y
8.28%
Revenues
1.57t
+10.42%
400,443,393,000484,346,075,000548,326,626,000613,750,337,000509,993,136,000710,547,146,300669,013,832,880682,508,015,670735,889,423,940839,686,478,170883,920,424,600960,307,423,0401,031,427,425,5301,113,425,921,0001,055,423,690,0001,152,975,698,0001,280,091,851,0001,375,328,745,0001,422,683,296,0001,570,886,131,000
Net income
195.86b
+691.83%
48,523,054,00058,948,245,00032,930,963,00049,467,008,00017,562,830,00050,185,946,00034,079,293,66058,399,564,79031,544,474,83042,930,060,24026,969,821,26031,580,584,390-15,151,848,39022,005,927,00012,753,425,00024,505,736,00042,239,518,000121,738,683,00024,734,511,000195,855,575,000
CFO
149.21b
+189.76%
48,962,960,00025,810,021,00031,326,248,00093,907,855,00020,110,498,00078,822,880,64045,023,829,91054,157,051,36025,945,213,40035,887,836,00015,377,371,370103,938,172,74047,499,563,37057,600,276,000100,981,257,00039,994,279,000118,214,603,000136,008,811,00051,492,294,000149,205,466,000
Dividend
Dec 29, 2025600 KRW/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Established in 1945 and headquartered in Seoul, South Korea, Daewoong Pharmaceutical Co., Ltd. is a global entity dedicated to the research, production, and international distribution of a diverse range of pharmaceutical products. Its extensive portfolio provides therapeutic solutions across numerous health disciplines, including treatments for central nervous system disorders, endocrine conditions, musculoskeletal ailments, nephrological issues, oncology, cardiovascular diseases, gastrointestinal complaints, and metabolic dysfunctions. The company further offers products addressing viral infections, pain relief, antacids, digestive problems, wound care, and nutritional supplements such as iron and multivitamins. Complementing its pharmaceutical offerings, Daewoong also supplies medical devices, notably COVID-19 PCR and IgG/IgM RDT diagnostic kits, along with viral transport media.
URL
https://www.daewoong.co.kr/kr/main/index
IPO date
Nov 01, 2002
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT